Adam Perlman > Latham & Watkins LLP > New York, United States > Lawyer Profile
Latham & Watkins LLP Offices

1271 Avenue of the Americas
NEW YORK
NY 10020
United States
- Firm Profile
- Go to...
Adam Perlman

Position
Adam Perlman, a nationally recognized first-chair patent trial lawyer and a Fellow of the American College of Trial Lawyers, represents brand-name pharmaceutical manufacturers and leading life sciences companies in intellectual property litigation.
Adam leverages more than 25 years of experience and a solutions-oriented approach to guide clients through every stage of major IP litigation, particularly Hatch-Waxman trials and Federal Circuit appeals. He advocates across a broad range of technologies and sectors, including:
-
- Pharmaceuticals
- Biotechnology and biologics
- Medical devices
As lead counsel in major patent litigation in US district courts and before the US Court of Appeals for the Federal Circuit, he distills complex concepts into compelling advocacy before judges and juries across the country. Adam also routinely litigates life sciences inter partes review proceedings before the US Patent and Trademark Office (USPTO). Adam has argued 11 times before the Federal Circuit since 2012, including before the en banc court in Alice Corp. v. CLS Bank International.
A recognized thought leader, Adam frequently speaks on patent litigation issues, including before the Association of Corporate Patent Counsel, the American Conference Institute Paragraph IV Disputes Master Symposium, the American Law Institute course “Trial of a Patent Case,” and other industry groups.
Adam has served on the firm’s Associates Committee and Training and Career Enhancement (TACE) Committee.
Top Tier Firm Rankings
- Insurance > Advice to policyholders
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- Finance > Capital markets: high-yield debt offerings
- Antitrust > Cartel
- International trade and national security > CFIUS
- Antitrust > Civil litigation/class actions: defense
- Finance > Commercial lending
- Finance > Commercial lending: Advice to bank lenders
- Intellectual property > Copyright
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Energy > Energy transactions: electric power
- Energy > Energy transactions: oil and gas
- Environment > Environment: litigation
- Environment > Environment: regulatory
- Environment > Environment: transactional
- Finance > Fintech
- Dispute resolution > General commercial disputes
- Healthcare > Life sciences
- Real estate > Land use/zoning
- Industry focus > Sport
- Healthcare > Life sciences
- Industry focus > Sport
- Healthcare > Life sciences
- Healthcare > Life sciences
- Healthcare > Life sciences
- Healthcare > Life sciences
- Finance > Fintech
- Intellectual property > Patents: licensing
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Media, technology and telecoms > Media and entertainment: litigation
- Media, technology and telecoms > Media and entertainment: transactional
- Antitrust > Merger control
- International trade and national security > National Security
- Healthcare > Life sciences
- Intellectual property > Patents: licensing
- Industry focus > Sport
- Industry focus > Sport
- Intellectual property > Patents: licensing
- Intellectual property > Patents: litigation (full coverage)
- Intellectual property > Patents: litigation (International Trade Commission)
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Finance > Project finance
- Real estate > Real estate
- Real estate > Real estate investment trusts (REITs)
- Energy > Renewable/alternative power
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Securities litigation: defense
- M&A/corporate and commercial > Shareholder activism
- Industry focus > Sport
- Finance > Structured finance: derivatives and structured products
- Finance > Structured finance: securitization
- Media, technology and telecoms > Technology transactions
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: contentious
- Tax > US taxes: non-contentious
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- M&A/corporate and commercial > Corporate governance
- International trade and national security > Customs, export controls and economic sanctions
- Industry focus > Education
- Energy > Energy regulation: electric power
- Energy > Energy regulation: oil and gas
- Government > Government contracts
- Insurance > Insurance: non-contentious
- Dispute resolution > International litigation
- Dispute resolution > Leading trial lawyers
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Financial services litigation
- Healthcare > Health insurers
- Media, technology and telecoms > Outsourcing
- Healthcare > Service providers
- Dispute resolution > International arbitration
- Dispute resolution > Leading trial lawyers
- Intellectual property > Trademarks: litigation
- Dispute resolution > Leading trial lawyers
- Finance > Financial services regulation
- Finance > Commercial lending > Advice to direct lenders/private credit
- Dispute resolution > Corporate investigations and white-collar criminal defense